Trade Evolus Inc - EOLS CFD

Evolus Company profile

About Evolus Inc

Evolus, Inc. is a beauty company that is focused on delivering products in the self-pay aesthetic market. The Company's primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers. Its commercial product is Jeuveau (prabotulinumtoxinA-xvfs), which is a prescription medicine designed to address the needs of the facial aesthetics market. Jeuveau is a 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines also known as frown lines, in adults. The Company commercially launched its product in the United States and Canada. Jeuveau is manufactured using Hi-Pure technology.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Evolus Inc revenues increased 76% to $99.7M. Net loss decreased 71% to $46.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Litigation settlement expenses decrease from $83.4M (expense) to $0K, Interest expense decrease of 87% to $1.4M (expense), Depreciation decrease of 91% to $317K (expense).